SG125229A1 - Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceuticalcompositions containing it - Google Patents

Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceuticalcompositions containing it

Info

Publication number
SG125229A1
SG125229A1 SG200601141A SG200601141A SG125229A1 SG 125229 A1 SG125229 A1 SG 125229A1 SG 200601141 A SG200601141 A SG 200601141A SG 200601141 A SG200601141 A SG 200601141A SG 125229 A1 SG125229 A1 SG 125229A1
Authority
SG
Singapore
Prior art keywords
gamma
preparation
crystalline form
ivabradine hydrochloride
pharmaceuticalcompositions
Prior art date
Application number
SG200601141A
Other languages
English (en)
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG125229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of SG125229A1 publication Critical patent/SG125229A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200601141A 2005-02-28 2006-02-21 Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceuticalcompositions containing it SG125229A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
SG125229A1 true SG125229A1 (en) 2006-09-29

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200601141A SG125229A1 (en) 2005-02-28 2006-02-21 Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceuticalcompositions containing it

Country Status (42)

Country Link
US (3) US7361650B2 (es)
EP (1) EP1707562B1 (es)
JP (1) JP4628974B2 (es)
KR (1) KR100835447B1 (es)
CN (1) CN100402502C (es)
AP (1) AP1956A (es)
AR (1) AR052926A1 (es)
AT (1) ATE396974T1 (es)
BR (1) BRPI0600796B8 (es)
CA (1) CA2537400C (es)
CO (1) CO5770097A1 (es)
CR (1) CR8249A (es)
CU (1) CU23616B7 (es)
CY (1) CY1109010T1 (es)
DE (1) DE602006001312D1 (es)
DK (1) DK1707562T3 (es)
EA (1) EA008465B1 (es)
ES (1) ES2308689T3 (es)
FR (1) FR2882555B1 (es)
GE (1) GEP20084467B (es)
GT (1) GT200600088A (es)
HK (1) HK1096659A1 (es)
HR (1) HRP20080406T5 (es)
IL (1) IL173959A0 (es)
JO (1) JO2515B1 (es)
MA (1) MA28134A1 (es)
ME (1) ME02747B (es)
MY (1) MY158129A (es)
NO (1) NO338481B1 (es)
NZ (1) NZ545578A (es)
PE (1) PE20061142A1 (es)
PL (1) PL1707562T3 (es)
PT (1) PT1707562E (es)
RS (1) RS50598B (es)
SA (1) SA06270040B1 (es)
SG (1) SG125229A1 (es)
SI (1) SI1707562T1 (es)
TW (1) TWI314143B (es)
UA (1) UA86595C2 (es)
UY (1) UY29406A1 (es)
WO (1) WO2006092492A1 (es)
ZA (1) ZA200601764B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
JP5632279B2 (ja) 2007-05-30 2014-11-26 アイエヌディー−スイフト ラボラトリーズ リミテッド 塩酸イバブラジンの調製方法及びポリモルフ
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
SI23290A (sl) 2010-02-12 2011-08-31 Krka D.D., Novo Mesto Nove oblike ivabradin hidroklorida
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013102919A1 (en) * 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
EP2781509B2 (en) * 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
SI2774606T1 (sl) 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
US11273162B2 (en) * 2016-04-01 2022-03-15 Mississippi State University Compositions and methods targeting HCN channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CA2537400C (fr) 2009-12-15
IL173959A0 (en) 2006-07-05
CU23616B7 (es) 2011-01-27
WO2006092492A1 (fr) 2006-09-08
NO20060948L (no) 2006-08-29
DK1707562T3 (da) 2008-10-13
PL1707562T3 (pl) 2008-08-29
MY158129A (en) 2016-08-30
UA86595C2 (ru) 2009-05-12
HRP20080406T3 (en) 2008-09-30
ME02747B (me) 2010-05-07
BRPI0600796B1 (pt) 2019-02-19
BRPI0600796B8 (pt) 2021-05-25
RS50598B (sr) 2010-05-07
US20060194963A1 (en) 2006-08-31
CU20060037A7 (es) 2008-06-30
US7361650B2 (en) 2008-04-22
NZ545578A (en) 2007-02-23
JP2006241156A (ja) 2006-09-14
HRP20080406T5 (en) 2008-11-30
TWI314143B (en) 2009-09-01
ES2308689T3 (es) 2008-12-01
EA200600320A1 (ru) 2006-08-25
GT200600088A (es) 2006-10-24
CR8249A (es) 2008-01-21
AP2006003521A0 (en) 2006-02-28
EP1707562A1 (fr) 2006-10-04
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
FR2882555B1 (fr) 2007-05-04
JP4628974B2 (ja) 2011-02-09
PE20061142A1 (es) 2006-12-30
US7867996B2 (en) 2011-01-11
KR20060095499A (ko) 2006-08-31
EP1707562B1 (fr) 2008-05-28
US20080153803A1 (en) 2008-06-26
US20090318417A1 (en) 2009-12-24
UY29406A1 (es) 2006-07-31
SA06270040B1 (ar) 2010-03-23
CO5770097A1 (es) 2007-06-29
MA28134A1 (fr) 2006-09-01
BRPI0600796A (pt) 2007-08-14
NO338481B1 (no) 2016-08-22
AU2006200857A1 (en) 2010-01-28
CY1109010T1 (el) 2014-07-02
ATE396974T1 (de) 2008-06-15
PT1707562E (pt) 2008-07-08
KR100835447B1 (ko) 2008-06-09
JO2515B1 (en) 2010-03-17
HK1096659A1 (en) 2007-06-08
DE602006001312D1 (de) 2008-07-10
AR052926A1 (es) 2007-04-11
SI1707562T1 (sl) 2008-10-31
AP1956A (en) 2009-02-18
GEP20084467B (en) 2008-08-25
CN1827602A (zh) 2006-09-06
EA008465B1 (ru) 2007-06-29
ZA200601764B (en) 2007-05-30
TW200640872A (en) 2006-12-01
FR2882555A1 (fr) 2006-09-01

Similar Documents

Publication Publication Date Title
SG125229A1 (en) Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceuticalcompositions containing it
TWI315306B (en) Bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AP1907A (en) Beta-crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical compositions containing it
ZA200608404B (en) Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
ZA200608403B (en) Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
ZA200601760B (en) Yd-crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical compositions containing it
EP2162438A4 (en) PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND CORRESPONDING POLYMORPHIDE
HK1133635A1 (en) Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3- benzazepine and intermediates thereof (r)-8--1--2345--1h-3-
HK1096386A1 (en) Indanyl-piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200603810B (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
IL186220A0 (en) Processes for the preparation of atomoxetine hydrochloride
PL1928883T3 (pl) Sposób otrzymywania chlorowodorku irynotekanu
HK1096097A1 (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
EP2114883A4 (en) PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE
AU2006200856B2 (en) beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200857B2 (en) y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200854B2 (en) bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
IL185730A0 (en) Process for preparation of sertraline hydrochloride form i
SI1940790T1 (sl) Polimorfna oblika lerkanidipin hidroklorida in postopek za njegovo pripravo